{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:41:30Z","timestamp":1762987290083,"version":"3.45.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jtocrr.2022.100440","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T20:46:57Z","timestamp":1669841217000},"page":"100440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-3856","authenticated-orcid":false,"given":"Andreas","family":"Rimner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Offin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etay","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphna Y.","family":"Gelblum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie F.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Guttmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan E.","family":"Eichholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsheen N.","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Namakydoust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"McCune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily H.","family":"Gelb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil K.","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"von Reibnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen D.","family":"Yorke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2022.100440_bib2","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN Solid Tumor Trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","article-title":"Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial","volume":"22","author":"Cho","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib6","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/JTO.0000000000000499","article-title":"Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial","volume":"10","author":"MacLeod","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib8","first-page":"45","article-title":"SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma","volume":"8","author":"Ashton","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtocrr.2022.100440_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtocrr.2022.100440_bib11","article-title":"Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma","volume":"8","author":"Curti","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtocrr.2022.100440_bib12","doi-asserted-by":"crossref","first-page":"137ra74","DOI":"10.1126\/scitranslmed.3003649","article-title":"Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses","volume":"4","author":"Seung","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtocrr.2022.100440_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2022.100440_bib14","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"151","author":"de Perrot","year":"2016","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtocrr.2022.100440_bib16","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtocrr.2022.100440_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2019.02.046","article-title":"Immunomodulatory effects of stereotactic body radiation\u00a0therapy: preclinical insights and clinical opportunities","volume":"110","author":"Marciscano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.jtocrr.2022.100440_bib26","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jtocrr.2022.100440_bib20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jtocrr.2022.100440_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2020.03.019","article-title":"Significant reduction of oncologic pulmonary death by local control for pulmonary oligometastases treated with stereotactic body radiotherapy","volume":"147","author":"Yamamoto","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib23","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/0284186X.2018.1481292","article-title":"Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung\u00a0cancer (NSCLC)","volume":"57","author":"von Reibnitz","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jtocrr.2022.100440_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cllc.2015.09.006","article-title":"Recurrence patterns and second primary lung cancers after stereotactic body radiation therapy for early-stage non-small-cell lung cancer: implications for surveillance","volume":"17","author":"Spratt","year":"2016","journal-title":"Clin Lung Cancer"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322001643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322001643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:37:48Z","timestamp":1762987068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364322001643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2666364322001643"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100440","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100440"}}